Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomised, double-blind, non-comparative phase II trial of ZD1839 (Iressa) [gefitinib] and placebo in combination with chemotherapy with docetaxel as first-line treatment in patients with metastatic breast cancer

Next Previous
X
Search
Trial Profile

A multicenter, randomised, double-blind, non-comparative phase II trial of ZD1839 (Iressa) [gefitinib] and placebo in combination with chemotherapy with docetaxel as first-line treatment in patients with metastatic breast cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2009

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gefitinib (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca

    • Most Recent Events

    • 12 May 2009 Actual end date (Jun 2005) added as reported by ClinicalTrials.gov.
    • 14 Dec 2007 Status changed from in progress to completed.
    • 12 Dec 2007 Results presented at SABCS 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top